Search tips
Search criteria 


Logo of ijpsychHomeCurrent issueInstructionsSubmit article
Indian J Psychiatry. 2001 Jul-Sep; 43(3): 257–263.
PMCID: PMC2956152



The aim of the present study was to assess the efficacy and safety of olanzapine in the treatment of schizophrenic patients. 27 patients were randomly assigned to treatment with olanzapine or haloperidol over 12 weeks. The primary efficacy measure was the mean change from baseline to endpoint in total scores on the Brief Psychiatric Rating Scale (BPRS) and assessing treatment emergent adverse events. Secondary measures were positive symptoms, negative symptoms, general psychopathology depression, anxiety and quality of life. Compared to haloperidol, olanzapine had equal effect in improving overall psychopathology, positive symptoms, and severity of schizophrenic illness. Olanzapine showed supehor improvement on negative symptoms and secondary depressive features. Commonest side effects were weight gain, sleepiness and increased duration of sleep. Olanzapine is effective in improving overall psychopathology including positive symptoms, negative and secondary depressive features in Indian patients with schizophrenia and it is safe and well tolerated at dosage between 5 to 20 mg/day

Keywords: Olanzapine, schizophrenia, treatment

Full Text

The Full Text of this article is available as a PDF (304K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989 May;154:672–676. [PubMed]
  • Beasley CM, Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 1996 Feb;14(2):111–123. [PubMed]
  • Beasley CM, Jr, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl) 1996 Mar;124(1-2):159–167. [PubMed]
  • Beasley CM, Jr, Hamilton SH, Crawford AM, Dellva MA, Tollefson GD, Tran PV, Blin O, Beuzen JN. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol. 1997 May;7(2):125–137. [PubMed]
  • Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996 Feb;14(2):87–96. [PubMed]
  • Bymaster F, Perry KW, Nelson DL, Wong DT, Rasmussen K, Moore NA, Calligaro DO. Olanzapine: a basic science update. Br J Psychiatry Suppl. 1999;(37):36–40. [PubMed]
  • Carlsson A. Neurocircuitries and neurotransmitter interactions in schizophrenia. Int Clin Psychopharmacol. 1995 Sep;10 (Suppl 3):21–28. [PubMed]
  • Casey DE. Side effect profiles of new antipsychotic agents. J Clin Psychiatry. 1996;57 (Suppl 11):40–52. [PubMed]
  • Harrow M, Yonan CA, Sands JR, Marengo J. Depression in schizophrenia: are neuroleptics, akinesia, or anhedonia involved? Schizophr Bull. 1994;20(2):327–338. [PubMed]
  • Heinrichs DW, Hanlon TE, Carpenter WT., Jr The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull. 1984;10(3):388–398. [PubMed]
  • Kane JM. Treatment of schizophrenia. Schizophr Bull. 1987;13(1):133–156. [PubMed]
  • Kane JM, Mayerhoff D. Do negative symptoms respond to pharmacological treatment? Br J Psychiatry Suppl. 1989 Nov;(7):115–118. [PubMed]
  • Kirkpatrick B, Carpenter WT., Jr Drug development and the deficit syndrome of schizophrenia. Biol Psychiatry. 1995 Sep 1;38(5):277–278. [PubMed]
  • Meltzer HY. The mechanism of action of novel antipsychotic drugs. Schizophr Bull. 1991;17(2):263–287. [PubMed]
  • Meltzer HY. Clozapine: is another view valid? Am J Psychiatry. 1995 Jun;152(6):821–825. [PubMed]
  • Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979 Apr;134:382–389. [PubMed]
  • Hemrick-Luecke SK, Snoddy HD, Fuller RW. Evaluation of nefazodone as a serotonin uptake inhibitor and a serotonin antagonist in vivo. Life Sci. 1994;55(7):479–483. [PubMed]
  • Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11–19. [PubMed]
  • Tollefson GD, Beasley CM, Jr, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry. 1997 Apr;154(4):457–465. [PubMed]
  • Tollefson GD, Sanger TM. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry. 1997 Apr;154(4):466–474. [PubMed]
  • Tollefson GD, Sanger TM, Lu Y, Thieme ME. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry. 1998 Mar;55(3):250–258. [PubMed]
  • Tran PV, Dellva MA, Tollefson GD, Beasley CM, Jr, Potvin JH, Kiesler GM. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry. 1997 May;58(5):205–211. [PubMed]

Articles from Indian Journal of Psychiatry are provided here courtesy of Medknow Publications